西南医科大学学报2019，Vol.42Issue(1)：90-92,3.DOI:10.3969/j.issn.2096-3351.2019.01.020
IgA肾病的生物标志物和靶向性新疗法
Biomarkers and new targeted therapies for IgA nephropathy
摘要
Abstract
IgA nephropathy (IgAN) is the most common type of primary glomerulonephritis in China and is also the main cause of end-stage renal disease. It has various clinical manifestations and different severities, and most patients have poor prognosis. However, the pathogenesis of IgAN remains unclear, and it has limited treatment methods in clinical practice, with symptomatic treatment as the most commonly used method. At present, there are no specific biomarkers for the diagnosis and progression of IgAN, and renal biopsy remains the gold standard; however, renal biopsy is an invasive examination and causes certain damage to patients, and thus it cannot be performed repeatedly to monitor the progression of the disease, which may lead to delayed diagnosis. Therefore, it is of vital importance to find new biomarkers and effective therapeutic targets associated with the early diagnosis, progression, and prognosis for IgAN.关键词
IgAN/生物标志物/靶向性治疗Key words
IgA nephropathy/Biomarker/Targeted therapy分类
医药卫生引用本文复制引用
朱梦莲,王丽..IgA肾病的生物标志物和靶向性新疗法[J].西南医科大学学报,2019,42(1):90-92,3.基金项目
国家自然科学基金(81641025) （81641025）
四川省第一批科技计划项目(2016JY0194) （2016JY0194）
中西医结合防治慢性肾疾病(17TD0046) （17TD0046）
